Добірка наукової літератури з теми "PARP1 Inhibitors"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "PARP1 Inhibitors".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "PARP1 Inhibitors"
Kam, Caleb M., Amanda L. Tauber, Stephan M. Levonis, and Stephanie S. Schweiker. "Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14." Future Medicinal Chemistry 12, no. 24 (December 2020): 2179–90. http://dx.doi.org/10.4155/fmc-2020-0218.
Повний текст джерелаMaluchenko, Natalya, Darya Koshkina, Anna Korovina, Vasily Studitsky, and Alexey Feofanov. "Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes." Cells 11, no. 21 (October 23, 2022): 3343. http://dx.doi.org/10.3390/cells11213343.
Повний текст джерелаZientara-Rytter, Kasia, Veronique T. Baron, Junguk Park, Pavel Shashkin, and Henry Zhu. "Abstract 6111: Design of a small molecule screening assay to detect DNA trapping of PARP1/2." Cancer Research 83, no. 7_Supplement (April 4, 2023): 6111. http://dx.doi.org/10.1158/1538-7445.am2023-6111.
Повний текст джерелаJi, Ming, Liyuan Wang, Nina Xue, Fangfang Lai, Sen Zhang, Jing Jin, and Xiaoguang Chen. "The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay." SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, no. 6 (April 20, 2018): 545–53. http://dx.doi.org/10.1177/2472555218767843.
Повний текст джерелаHalazonetis, Thanos D., Michalis Petropoulos, Giacomo G. Rossetti, Angeliki Karamichali, Alena Freudenmann, Luca Iacovino, Vasilis Dionellis, and Sotirios K. Sotiriou. "Abstract 1566: DNA damage generated by transcription-replication conflicts explains the synthetic lethality of PARP inhibitors with homologous recombination deficiency." Cancer Research 83, no. 7_Supplement (April 4, 2023): 1566. http://dx.doi.org/10.1158/1538-7445.am2023-1566.
Повний текст джерелаWang, Kai, Yizhou Wu, Lizhu Lai, Xin Wang, and Shuya Sun. "How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level." PLOS ONE 18, no. 8 (August 15, 2023): e0290176. http://dx.doi.org/10.1371/journal.pone.0290176.
Повний текст джерелаYin, Ling, and Junjie Chen. "Abstract 6098: Genome wide CRISPR screen reveals genetic vulnerabilities of next generation PARP1 inhibitor AZD5305." Cancer Research 83, no. 7_Supplement (April 4, 2023): 6098. http://dx.doi.org/10.1158/1538-7445.am2023-6098.
Повний текст джерелаKrastev, Dragomir B., Andrew J. Wicks, and Christopher J. Lord. "PARP Inhibitors – Trapped in a Toxic Love Affair." Cancer Research 81, no. 22 (November 15, 2021): 5605–7. http://dx.doi.org/10.1158/0008-5472.can-21-3201.
Повний текст джерелаNieborowska-Skorska, Margaret, Paulina Podszywalow-Bartnicka, Silvia Maifrede, Bac Viet Le, Monika Toma, Peter Valent, Tomasz Sliwinski, et al. "PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions." Blood 132, Supplement 1 (November 29, 2018): 3000. http://dx.doi.org/10.1182/blood-2018-99-115041.
Повний текст джерелаTutt, Andrew. "Abstract ED12-3: ATR inhibitors and PARP1 selective PARP inhibitors." Cancer Research 83, no. 5_Supplement (March 1, 2023): ED12–3—ED12–3. http://dx.doi.org/10.1158/1538-7445.sabcs22-ed12-3.
Повний текст джерелаДисертації з теми "PARP1 Inhibitors"
Alkhateeb, Hebah, Gregory A. Ordway, W. Drew Gill, Joshua B. Coleman, Hui Wang-Heaton, Russell W. Brown, Michelle Chandley, et al. "PARP1 inhibition produces unique antidepressant effects in an animal model of treatment-resistant depression." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/49.
Повний текст джерелаD'Angeli, Floriana. "Biomolecular effects and bioclinical applications of PARPs inhibitors." Doctoral thesis, Università di Catania, 2017. http://hdl.handle.net/10761/3832.
Повний текст джерелаGeraets, Liesbeth. "Dietary PARP-1 inhibitors as anti-inflammatory compounds." Maastricht : Maastricht : Universitaire Pers ; University Library, Universiteit Maastricht [host], 2008. http://arno.unimaas.nl/show.cgi?fid=14252.
Повний текст джерелаKumpan, Katerina. "Structure-activity studies on inhibitors of the tankyrases." Thesis, University of Bath, 2014. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.619223.
Повний текст джерелаAhmed, Zina. "Poly-ADP ribos polymeras (PARP) inhibitorers effekt på bröstcancer : Poly-ADP ribos polymeras (PARP) inhibitorers effekt på bröstcancer." Thesis, Umeå universitet, Kemiska institutionen, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-103397.
Повний текст джерелаAlmeida, Gilberto Serrano de. "Pre-clinical imaging evaluation of the PARP inhibitor rucaparib." Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/2033.
Повний текст джерелаHukkanen, M. (Mikko). "DNA damage sensitization of breast cancer cells with PARP10/ARTD10 inhibitor." Master's thesis, University of Oulu, 2019. http://jultika.oulu.fi/Record/nbnfioulu-201909062843.
Повний текст джерелаCastroviejo, Bermejo Marta. "RAD51 as functional biomarker to select tumors for PARP inhibitor treatment." Doctoral thesis, Universitat Autònoma de Barcelona, 2019. http://hdl.handle.net/10803/667273.
Повний текст джерелаPoly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective anticancer drugs in cancers with defective homologous recombination DNA repair (HRR), including cancers with mutations in BRCA1 and BRCA2 (BRCA1/2), which also display enhanced sensitivity to DNA damaging chemotherapy such as platinum salts. Several mechanisms of PARPi resistance have been described in tumors with germline mutations in BRCA1/2 (gBRCA) and there are also other tumors with wild type BRCA1/2 (non-BRCA) that benefit from PARPi treatment. Therefore, there is a need to develop robust biomarkers to better select HRR- deficient tumors and extend the use of PARP inhibition in new indications, as well as identify PARPi-resistant tumors and study combination treatment options that enhance clinical efficacy and utility of PARPi. We evaluated the activity of the PARPi olaparib in patient-derived tumor xenografts (PDXs) from patients with breast or ovarian cancer, both with and without gBRCA mutation, exhibiting differential response to PARPi. We studied the in vivo mechanisms of PARPi resistance and sensitivity in these models and tested the formation of RAD51 nuclear foci by immunofluorescence as biomarker of HRR functionality and PARPi response in PDXs and routine clinical samples. We also tested the antitumor activity of the WEE1i AZD1775 and the ATMi AZD0156 as single agent and in combination with PARPi in PDXs. The measurement of replication stress biomarkers was assessed to study the mechanisms of action of these treatment strategies. Within the gBRCA PDXs panel, no BRCA1/2 secondary mutations were found in the PARPi resistant models. BRCA1 nuclear foci were detected in six out of ten PARPi-resistant PDXs, in keeping with expression of hypomorphic BRCA1 isoforms. Loss of 53BP1 and FAM35A were identified in three PDXs, one of which concomitantly expressed an hypomorphic BRCA1 protein. The common feature in all PDXs with primary or acquired PARPi resistance was the formation of RAD51 nuclear foci. Consistently, lack of RAD51 foci was always associated with clinical response to PARPi in patients treated with these agents. When studying the mechanisms of PARPi sensitivity in the non-gBRCA PDX cohort, BRCA1 promoter hypermethylation and alterations in HRR-related genes were found in PARPi- sensitive models. Again, the unique common feature in all PDXs that exhibited tumor regression upon PARPi treatment is the absence of RAD51 nuclear foci. The RAD51 assay could be performed in untreated samples and was highly discriminative of PARPi sensitivity versus PARPi resistance in different PDX cohorts and outperformed the Myriad’s myChoice® HRD genomic test. In routine clinical samples from patients with hereditary breast and ovarian cancer (HBOC) syndrome, all PALB2-related tumors were classified as HRR-deficient by the RAD51 score. In PDXs, PARPi resistance in BRCA1-altered tumors could be reverted upon combination of PARPi with WEE1 or ATM inhibitors and both combination strategies resulted in exacerbated induction of replication stress (RS) in combination- sensitive PDXs. With the results obtained in this thesis, it can be concluded that gBRCA tumors achieve PARPi resistance by several mechanisms that restore HRR function, all detected by the presence of RAD51 nuclear foci. This functional assay also enables the identification of PARPi-sensitive non-gBRCA tumors independently of the mechanisms of HRR-deficiency, thereby being a promising biomarker to better select patients for PARP inhibition and broaden the population who may benefit from this therapy. Our study also supports the clinical development of PARPi combinations such as those with WEE1 and ATM inhibitors and highlighted the induction of RS as the major mechanisms of action of these drugs.
Löser, Dana A. "Investigating the mechanisms by which PARP inhibitors increase sensitivity to DNA damaging agents." Thesis, University of Sussex, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.505912.
Повний текст джерелаGuillot, Clément. "Potentiel des inhibiteurs de poly(ADP-ribose) polymérases seuls ou en combinaison avec la radiothérapie comme nouvelle option thérapeutique pour le carcinome hépatocellulaire." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10281.
Повний текст джерелаHepatocellular carcinoma is the third cause of cancer related death. Due its often late diagnosis and advanced stage, a limited number of patients can benefit from curative treatments. There is thus a constant need for new treatment strategies for patients with hepatocellular carcinoma. Targeting DNA repair pathways to sensitize tumor cells to chemoor radiotherapeutic treatments is now a common strategy under investigation for cancer treatment with inhibitors of poly(ADP-ribose) polymerases (PARP) showing great potential. The aim of this work was to evaluate the potential of PARP inhibitors alone and in combination with radiation therapy as a new strategy for the treatment of hepatocellular carcinoma. We first analyzed the expression and activity of different PARP genes in a panel of liver cancer cell lines and primary human hepatocytes as well as their DNA repair capacity and assess the impact of PARP inhibitors alone and in combination with ionizing radiation in these models on cell survival. A large range in expression of PARP family members, PARP activity and sensitivity to ABT-888 in the panel of liver cells was observed as well as differential excision/synthesis repair capacity. Finally, we showed that ABT-888 sensitizes liver cancer cells to the cell killing effects of ionizing radiation. PARP inhibitors show great potential for improving radiation therapy strategies used in the management of hepatocellular carcinoma
Книги з теми "PARP1 Inhibitors"
Curtin, Nicola J., and Ricky A. Sharma, eds. PARP Inhibitors for Cancer Therapy. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0.
Повний текст джерелаCurtin, Nicola J., and Ricky A. Sharma. PARP Inhibitors for Cancer Therapy. Humana, 2018.
Знайти повний текст джерелаCurtin, Nicola J., and Ricky A. Sharma. PARP Inhibitors for Cancer Therapy. Springer International Publishing AG, 2015.
Знайти повний текст джерелаCurtin, Nicola J., and Ricky A. Sharma. PARP Inhibitors for Cancer Therapy. Humana Press, 2015.
Знайти повний текст джерелаZhang, Jei. PARP As a Therapeutic Target. Taylor & Francis Group, 2002.
Знайти повний текст джерелаZhang, Jei. PARP As a Therapeutic Target. Taylor & Francis Group, 2002.
Знайти повний текст джерелаHodgkiss, Andrew. Psychiatric consequences of cancer treatments: ‘small molecule’ molecularly targeted agents. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0008.
Повний текст джерелаPARP as a Therapeutic Target (Handbooks in Pharmacology and Toxicology). CRC, 2002.
Знайти повний текст джерелаCurtin, Nicola, and Péter Bay, eds. PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer. MDPI, 2023. http://dx.doi.org/10.3390/books978-3-0365-8157-6.
Повний текст джерелаЧастини книг з теми "PARP1 Inhibitors"
Kotova, Elena, Aaron D. Pinnola, and Alexei V. Tulin. "Small-Molecule Collection and High-Throughput Colorimetric Assay to Identify PARP1 Inhibitors." In Methods in Molecular Biology, 491–516. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-270-0_29.
Повний текст джерелаPriyancy, J., and D. P. Bhumika. "Design and Synthesis of Novel Poly ADP-ribose Polymerase 1 (PARP1) Inhibitors for the Treatment of Solid Tumors." In Special Publications, 31–35. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781839160783-00031.
Повний текст джерелаSchwab, Manfred. "PARP Inhibitors." In Encyclopedia of Cancer, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_4395-2.
Повний текст джерелаMateo, Joaquin, Timothy A. Yap, and Johann S. De Bono. "PARP Inhibitors." In Management of Castration Resistant Prostate Cancer, 253–64. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1176-9_18.
Повний текст джерелаDearman, Charles, Ricky A. Sharma, and Nicola J. Curtin. "Biomarkers for PARP Inhibitors." In Cancer Drug Discovery and Development, 553–79. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_24.
Повний текст джерелаDaugherty, Larry C., Brandon J. Fisher, Christin A. Knowlton, Michelle Kolton Mackay, David E. Wazer, Anthony E. Dragun, James H. Brashears, et al. "PARP Inhibitors (Poly(ADP-Ribose) Polymerase Inhibitors)." In Encyclopedia of Radiation Oncology, 611. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_752.
Повний текст джерелаMcCrudden, Cian M., and Kaye J. Williams. "The Vasoactivity of PARP Inhibitors." In Cancer Drug Discovery and Development, 299–311. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_12.
Повний текст джерелаShalinsky, David R., Cherrie K. Donawho, Gerrit Los, and Joann P. Palma. "Preclinical Chemosensitization by PARP Inhibitors." In Cancer Drug Discovery and Development, 225–60. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_9.
Повний текст джерелаSunada, Shigeaki, and Yoshio Miki. "PARP Inhibitors: Mechanism of Action." In Hereditary Breast and Ovarian Cancer, 281–92. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-4521-1_18.
Повний текст джерелаCanan, Stacie S. "Structure Based Design of PARP Inhibitors." In Cancer Drug Discovery and Development, 205–21. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_8.
Повний текст джерелаТези доповідей конференцій з теми "PARP1 Inhibitors"
Pignochino, Ymera, Federica Capozzi, Lorenzo D’ambrosio, Carmine Dell’aglio, Marco Basiricò, Paola Boccone, Erica Palesandro, et al. "Abstract 3709: PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR)." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3709.
Повний текст джерелаHopkins, Todd A., Yan Y. Shi, Enrico L. DiGiammarino, Sanjay C. Panchal, Gui-Dong G. Zhu, Thomas D. Penning, Eric F. Johnson, and David Maag. "Abstract 2850: Talazoparib (BMN-673) possesses greater PARP1 trapping activity than structurally distinct PARP inhibitors with identical PARP1 binding properties." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2850.
Повний текст джерелаGill, Sonja J., Ruth Macdonald, Carmen Pin, Rob Collins, Emilyanne Leonard, Gareth Maglennon, Andy Pike, et al. "Abstract 1374: The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1374.
Повний текст джерелаLu, Zhen, Wequn Mao, Lan Pang, Janice M. Santiago-O'Farrill, Haling Yang, Ahmed Ahmed, Hariprasad Vankayalapati, and Robert C. Bast. "Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-324.
Повний текст джерелаTelli, ML. "Abstract ES12-1: Clinical indications of PARP1 inhibitors and other targets." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-es12-1.
Повний текст джерелаDeng, Ou, Sweta Dash, Thales Nepomuceno, Ming D. Han, Bin Fang, Doug Marchion, Alvaro N. Monteiro, and Uwe Rix. "Abstract B022: PARP1 complex composition as a predictor of response to PARP inhibitors in BRCA-linked ovarian carcinoma." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-b022.
Повний текст джерелаHopkins, Todd A., Julie L. Wilsbacher, Enrico L. DiGiammarino, Sanjay C. Panchal, Gui-Dong Zhu, Thomas D. Penning, Eric F. Johnson, and David Maag. "Abstract C52: PARP1 trapping activity of PARP inhibitors is associated with cytotoxicity in both cancer cells and healthy bone marrow." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-c52.
Повний текст джерелаDeng, Ou, Sweta Dash, Thales Nepomuceno, Bin Fang, Douglas Marchion, John Koomen, Alvaro N. Monteiro, and Uwe Rix. "Abstract P018: Integrative proteomics of PARP1 protein complexes and post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors." In Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1535-7163.targ-21-p018.
Повний текст джерелаGay, Carl M., Pan Tong, Lerong Li, C. Allison Stewart, Triparna Sen, Bonnie S. Glisson, John V. Heymach, Jing Wang, and Lauren Averett Byers. "Abstract 2822: ATR inhibitors are active as single agents and in combination with PARP1 and ATM inhibitors in molecularly distinct subsets of small cell lung cancer models." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2822.
Повний текст джерелаMukhopadhyay, Asima, Nicola Curtin, and Richard Edmondson. "Clinico-pathological correlation of homologous recombination status in epithelial ovarian cancer: Surgeon’s perspective." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685292.
Повний текст джерелаЗвіти організацій з теми "PARP1 Inhibitors"
Cai, Zhaolun, Chunyu Liu, Chen Chang, Chaoyong Shen, Yuan Yin, Xiaonan Yin, Zhiyuan Jiang, et al. Comparative safety of PARP inhibitors in cancer: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0018.
Повний текст джерелаYazinski, Stephanie. Novel Mechanisms of PARP Inhibitor Resistance in BRCA1-Deficient Breast Cancers. Fort Belvoir, VA: Defense Technical Information Center, December 2013. http://dx.doi.org/10.21236/ada612869.
Повний текст джерелаYazinski, Stephanie. Novel Mechanisms of PARP Inhibitor Resistance in BRCA1-Deficient Breast Cancers. Fort Belvoir, VA: Defense Technical Information Center, December 2014. http://dx.doi.org/10.21236/ada614186.
Повний текст джерелаDent, Paul, and Yong Tang. PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells. Fort Belvoir, VA: Defense Technical Information Center, June 2011. http://dx.doi.org/10.21236/ada555901.
Повний текст джерелаKonstantinopoulos, Panagiotis. A Gene Expression Profile of BRCAness that Predicts for Responsiveness to Platinum and PARP Inhibitors. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada613331.
Повний текст джерелаZhang, Meilin, Jian Song, Hongguang Yang, Feng Jin, and Ang Zheng. Efficacy and safety of PARP inhibitors in breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0105.
Повний текст джерелаShao, Fengping, Shanyang He, Yanyun Duan, Yunhe Zhao, Yinguang LI, and Lan Jing. A meta-analysis of efficacy of PARP inhibitors versus conventional therapy or placebo in various cancers patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2020. http://dx.doi.org/10.37766/inplasy2020.6.0013.
Повний текст джерелаWu, Meng, HongMei Wang, and ZhengXiang Han. Comparison of PARP Inhibitors as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0033.
Повний текст джерелаShea, Lonnie D. Identification of a PARP Inhibitor Sensitivity Signature in Breast Cancer Using a Novel Transcription Factor Activity Array. Fort Belvoir, VA: Defense Technical Information Center, March 2012. http://dx.doi.org/10.21236/ada559941.
Повний текст джерелаDeSoto, Joseph A. The Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, September 2008. http://dx.doi.org/10.21236/ada502786.
Повний текст джерела